Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: jbershad who wrote (1393)	5/28/1998 10:36:00 PM
From: Robert Northington	Read Replies (1) \| Respond to of 2173

Here is a website for a private company that is working in the same area as Amln. www.insmed.com They were founded at UVA by Dr. Joseph Larner and things are going well for them. Dillon Read has kicked some venture money over the last couple of years. I am a shareholder so I will let the company's info speak for itself. BTW we were very jealous when Amylyn was going public & getting all the cash but now it doesn't feel so bad.

To: jbershad who wrote (1393)	6/3/1998 11:06:00 PM
From: arnie h	Read Replies (2) \| Respond to of 2173

Hi Jbershad: I like to check in every once in a while; so I thought I'd take a crack at answering your question about why the current weakness. Seems to me to be related to the Ergoset rejection. The 'Logic' for sellers would be something like this - "J&J ditched AMLN to hook up with Ergoset. Obviously, they think more of Ergoset's chances than of AMLN's. Ergoset gets turned down so, ergo, AMLN doesn't have much of a chance of getting approval". That's my guess and the fact that the whole market is heading south quickly doesn't help either. regards, Arnie alias Arnold (or vice versa).